The effects of somapacitan and daily GH on glucose metabolism and insulin resistance were similar in all the trials, except that FPG, fasting serum insulin and HOMA-IR changes from baseline were higher for daily GH than somapacitan in treatment-naïve patients at week 34. Here, GH1 is linked to Insulin resistance.